Discover our pipeline and understand how our targeted approaches are being developed.
Driving discovery through the unique exploitation of cross-discipline expertise in drug development
Sitryx is building a broad and differentiated pipeline by identifying novel targeted approaches based on how changes in metabolism modulate immune cell function.
Program | Hit-to-Lead | Lead Optimisation | Pre-clinical | Partner |
---|---|---|---|---|
SIT-052SEN | Idiopathic pulmonary fibrosis | |||
SIT-033KIN | Inflammatory bowel disease | |||
Discovery Pipeline | Multiple | |||
SIT-011PTM | Multiple Sclerosis | |||
SIT-022MLE | Inflammatory bowel disease | |||
SIT-047OCM | Systemic lupus erythematosus |
Intervening in cell metabolism, to reverse and resolve inflammation and tissue damage, leading to better outcomes.
Offering the potential for a broader population of patients to achieve remission in a range of severe diseases in immunology and oncology.